Previous 10 | Next 10 |
Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast (RS) status Durable and sustained red blood cell transfusion independence, increases in hemoglobin levels and reduction in transfusion burden o...
2024-05-23 17:49:01 ET Summary Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown statistical evidence supporting the effectiveness...
2024-05-03 00:30:12 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2024 Earnings Call Transcript
2024-05-02 12:32:10 ET Geron Corporation (GERN) Q1 2024 Earnings Conference Call May 2, 2024 8:00 am ET Corporate Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman, President and Chief Executive Officer Faye Feller - Exec...
2024-05-02 07:08:56 ET More on Geron Geron: FDA PDUFA Review With Continued Imetelstat Advancement Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Q1 2024 Earnings Previe...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelsta...
2024-05-01 16:23:58 ET Summary Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Advisory Committee already voted in favor of imetels...
2024-05-01 11:38:49 ET More on Geron Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Baird downgrades...
2024-04-30 13:42:09 ET More on Geron Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA TD Cowen starts ...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...